CliffBio
small molecule

FERRIPROX

DEFERIPRONE

Loss of exclusivityOctober 2029latest FDA-listed patent expiry
CompanyChiesi Usa, Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameFERRIPROX
Active ingredientDEFERIPRONE
Strength100MG/ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2015
Marketing statusRX

Listed patents

PatentExpiresType
8703156October 2029product

Regulatory exclusivity

CodeExpires
ODE-417April 2028
ODE-418April 2028
ODE-419April 2028

More from Chiesi Usa, Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

FERRIPROX patent cliff — loss of exclusivity October 2029 | CliffBio